河北医科大学学报

• 论著 • 上一篇    下一篇

负荷量加高维持量阿托伐他汀对ACS行PCI患者炎症因子及血管内皮功能的影响

  

  1. 河北北方学院附属第二医院检验科,河北 宣化 075100
  • 出版日期:2018-10-25 发布日期:2018-09-27
  • 作者简介:贾慧宇(1982-),女,河北宣化人,河北北方学院附属第二医院主管检验师,医学学士,从事临床检验学研究。
  • 基金资助:
    张家口市市级科技计划项目(1621061D)

Effect of atorvastatin in a load capacity and high maintaining dose on the inflammatory cytokines and vascular endothelial function in ACS patients underwent PCI#br#

  1. Department of Laboratory Medicine, the Second Affiliated Hospital ofHebei North University, Xuanhua 075100, China
  • Online:2018-10-25 Published:2018-09-27

摘要: [摘要]〓
〖HTH〗目的〖HTSS〗〖KG*2〗探讨负荷量加高维持量阿托伐他汀对急性冠状动脉综合征(acute coronary syndrome,ACS)行经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)患者炎症因子及血管内皮功能的影响。
〖HTH〗方法〖HTSS〗〖KG*2〗选取行PCI的ACS患者150例,随机分为观察组和对照组各75例。2组均进行冠状动脉造影及PCI,并口服常规治疗ACS药物。对照组每晚睡前口服阿托伐他汀20 mg/次。观察组于PCI术前每晚睡前口服阿托伐他汀80 mg/次,术后减至40 mg/次每晚睡前口服,4周后改为20 mg/次每晚睡前口服。2组于4周后进行对比评价,并维持服药最少2年以上。2组于PCI术前、术后1 d、术后4周测定超敏C反应蛋白(hypersensitive Creactive protein,hsCRP)、肿瘤坏死因子α(tumor necrosing factor alpha,TNFα)、白细胞介素6(interleukin6,IL6)、白细胞介素18(interleukin18,IL18)、一氧化氮(nitric oxide,NO)、内皮素1(endothelin1,ET1)、血管性假血友病因子(von Willebrand factor,vWF)、血小板表面活性标志蛋白P选择素(PSelectin/CD62p)、血小板膜糖蛋白Ⅱb/Ⅲa受体复合物(GPⅡb/Ⅲa)。
〖HTH〗结果〖HTSS〗〖KG*2〗2组hsCRP、TNFα、IL6和IL18均先升高后降低的趋势,但观察组在术后4周下降幅度更大,2组组间、时点间、组间·时点间交互作用差异均有统计学意义(P<005);2组NO均为先降低后升高,但观察组升高幅度更大,2组ET1和v WF均先升高后降低,但观察组降低幅度更大,2组组间、时点间、组间·时点间交互作用差异均有统计学意义(P<005);2组CD62p、GPⅡb/Ⅲa均呈先升高后降低的趋势,但观察组在术后4周下降幅度更大,2组组间、时点间、组间·时点间交互作用差异均有统计学意义(P<005) 。
〖HTH〗结论〖HTSS〗〖KG*2〗负荷量加高维持量阿托伐他汀可有效抑制ACS行PCI患者炎症反应及血小板活化,有效改善血管内皮功能和心功能,具有较高的应用价值,值得临床推广。

关键词: 冠心病, 阿托伐他汀, 炎症因子

Abstract: [Abstract] Objective〖HTSS〗〓To explore the effect of atorvastatin in a load capacity and high maintaining dose on the inflammatory cytokines and vascular endothelial function in acute coronary syndrome(ACS) patients underwent percutaneous coronary intervention(PCI).
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓One hundred and fifty  patients with ACS who underwent PCI were randomly divided into observation group and control group with 75 cases each. Coronary angiography and PCI were performed in both groups, and conventional ACS drugs were given orally. The control group received oral atorvastatin 20 mg/time before going to bed every night. Observed group received oral atorvastatin 80 mg/time before bed every night before PCI, postoperatively reduced to 40 mg/time before going to bed every night, and changed to 20 mg every night before going to bed. Two groups of patients undergo comparative evaluation after 4 weeks, and maintain medication for a minimum of 2 years. Highsensitivity Creactive protein(hsCRP), tumor necrosing factor alpha(TNFα), interleukin6(IL6), interleukin18(IL18), nitric oxide(NO), endothelin1(ET1), von Willebrand factor(vWF), PSelectin(CD62p), GPⅡb/Ⅲa were measured before PCI, 1 day after surgery, and 4 weeks after operation in two groups of patients.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓The hsCRP, TNFα, IL6 and IL18 levels in both groups were increased first and then decreased, but those in the observation group were decreased more significantly at 4 weeks postoperatively. The two groups had intergroup and time points. There was a statistically significant difference in the interaction between the two groups(P<005). The NO in both groups were decreased first and then increased, but the increase was greater in the observation group. Both ET1 and vWF were increased first and then decreased, but those in the observation group were decreased more significantly. There was a statistically significant difference in the interactions among groups, time points, and between groups(P<005). In both groups, CD62p and GPⅡb/Ⅲa were increased first and then decreased, but those in the observation group were decreased more significantly at 4 weeks postoperatively. The interactions among groups, time points, and between groups were similar between the two groups. The difference was statistically significant(P<005).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓The loading and high maintenance atorvastatin can effectively inhibit the inflammatory response and platelet activation in patients with ACS and effectively improve the vascular endothelial function and cardiac function. It has high application value and is worthy of clinical promotion.

Key words: coronary disease, atorvastatin, inflammatory factors